In the After-hours session last night, Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) surged 33.16% to $42.65 after a report of phase 1 clinical trial of RP-A501,
Shares of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) soared 10.93% after the company announced today the 2020 financial results of the Third quarter ended September 30,
At Stocktstelegraph.com, we are committed to helping investors make smart and profitable decisions. Our goal is to make investing easier and more accessible to everyone. We strive to provide the best and most reliable market information, news and analysis to ensure that our readers can make informed decisions.